Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Amortization - Intangibles (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Amortization - Intangibles for 16 consecutive years, with $855000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization - Intangibles fell 35.91% to $855000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a 17.66% decrease, with the full-year FY2024 number at $5.3 million, down 4.89% from a year prior.
  • Amortization - Intangibles was $855000.0 for Q3 2025 at Harvard Bioscience, down from $1.2 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $1.6 million in Q4 2022 to a low of $855000.0 in Q3 2025.
  • A 5-year average of $1.4 million and a median of $1.4 million in 2023 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: grew 9.92% in 2022, then plummeted 35.91% in 2025.
  • Harvard Bioscience's Amortization - Intangibles stood at $1.5 million in 2021, then grew by 9.92% to $1.6 million in 2022, then fell by 13.1% to $1.4 million in 2023, then dropped by 9.37% to $1.3 million in 2024, then plummeted by 31.98% to $855000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Amortization - Intangibles are $855000.0 (Q3 2025), $1.2 million (Q2 2025), and $1.2 million (Q1 2025).